News from halozyme therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 24, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Appoints Michael J. Labarre As Chief Scientific Officer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today named Michael...

Aug 10, 2015, 16:05 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Reports Second Quarter 2015 Financial Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported...

Aug 06, 2015, 12:15 ET
Halozyme Therapeutics, Inc. Logo.

UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery

 Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Pancreas Center at the University of California, San Francisco (UCSF) has...

Aug 05, 2015, 16:31 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Appoints Jeffrey W. Henderson To Board

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...

Aug 03, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme to Host Second Quarter 2015 Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2015 on Monday, August 10,...

Jul 31, 2015, 07:55 ET

Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer

 Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") and Halozyme...

Jun 19, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will present at the JMP Securities 2015 Life Sciences Conference in New York, on Wednesday, June...

Jun 05, 2015, 09:00 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Announces Plans For CFO Transition, Names Laurie Stelzer CFO

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech company, today announced its chief financial officer David Ramsay will retire...

Jun 03, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with AbbVie (NYSE: ABBV) to...

May 31, 2015, 11:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim...

May 27, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment

Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today a global...

May 12, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The UBS 2015 Global Health Care Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will present at the UBS 2015 Global Health Care Conference in New York, on Monday, May 18th,...

May 11, 2015, 16:05 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Reports First Quarter 2015 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported...

May 07, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas,...

May 04, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme To Host First Quarter 2015 Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2015 on Monday, May 11,...

Apr 20, 2015, 08:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today shared...

Apr 13, 2015, 09:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...

Apr 08, 2015, 09:15 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Provides Update Following Type B FDA Meeting

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it plans...

Mar 23, 2015, 09:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...

Mar 10, 2015, 09:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous...